Vincent Miller

Vincent Miller

UNVERIFIED PROFILE

Are you Vincent Miller?   Register this Author

Register author
Vincent Miller

Vincent Miller

Publications by authors named "Vincent Miller"

Are you Vincent Miller?   Register this Author

100Publications

3409Reads

12Profile Views

MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel R1004G Mutation.

Oncologist 2019 Aug 7. Epub 2019 Aug 7.

Department of Internal Medicine, Division of Hematology/Oncology, UC Davis School of Medicine, UC Davis Comprehensive Cancer Center, Sacramento, California, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0230DOI Listing
August 2019

Pan-Cancer Analysis of Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.

Oncologist 2019 Jul 10. Epub 2019 Jul 10.

Johns Hopkins University School of Medicine and Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0214DOI Listing
July 2019

Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.

Cancer 2019 Apr 24;125(7):1185-1199. Epub 2018 Dec 24.

Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California San Diego, San Diego, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31921DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433468PMC
April 2019

Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.

J Neurooncol 2019 Mar 9;142(1):111-118. Epub 2018 Dec 9.

Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11060-018-03070-2
Publisher Site
http://dx.doi.org/10.1007/s11060-018-03070-2DOI Listing
March 2019

Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion.

J Thorac Oncol 2019 Feb;14(2):e29-e30

City of Hope Comprehensive Cancer Center, Duarte, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.10.169DOI Listing
February 2019

Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.

J Thorac Oncol 2019 Jan 26;14(1):54-62. Epub 2018 Sep 26.

Department of Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.09.014DOI Listing
January 2019

Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.

Cancers (Basel) 2018 Dec 21;11(1). Epub 2018 Dec 21.

Department of Medicine, Division of Hematology/Oncology and Center for Personalized Cancer Therapy, University of California San Diego, 3855 Health Science Drive #0987, La Jolla, CA 92093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11010011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356731PMC
December 2018

Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutation.

Lung Cancer 2018 10 31;124:86-89. Epub 2018 Jul 31.

Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, CA 92868, USA; Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002183050
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2018.07.043DOI Listing
October 2018

Complete Response to a Fibroblast Growth Factor Receptor Inhibitor in a Patient With Head and Neck Squamous Cell Carcinoma Harboring Amplifications.

JCO Precis Oncol 2018 31;2. Epub 2018 Aug 31.

Ecaterina Ileana Dumbrava, Rasha Alfattal, and Apostolia Maria Tsimberidou, The University of Texas MD Anderson Cancer Center, Houston, TX; and Vincent A. Miller, Foundation Medicine, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.18.00100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528487PMC
August 2018

Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma.

Cancer Discov 2018 07 17;8(7):822-835. Epub 2018 May 17.

Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-0099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030433PMC
July 2018

Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study.

Health Aff (Millwood) 2018 05;37(5):765-772

Amy P. Abernethy is chief medical officer and chief scientific officer at Flatiron Health.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1377/hlthaff.2017.1579DOI Listing
May 2018

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

J Clin Oncol 2018 04 26;36(12):1199-1206. Epub 2018 Jan 26.

Jessica J. Lin, Satoshi Yoda, Beow Y. Yeap, Ibiayi Dagogo-Jack, Nicholas A. Jessop, Ginger Y. Jiang, Long P. Le, Aaron N. Hata, Justin F. Gainor, Anthony J. Iafrate, and Alice T. Shaw, Massachusetts General Hospital, Boston; Alexa B. Schrock, Kyle Gowen, Philip J. Stephens, Jeffrey S. Ross, Siraj M. Ali, and Vincent A. Miller, Foundation Medicine, Cambridge, MA; Viola W. Zhu and Sai-Hong Ignatius Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; Melissa L. Johnson, Sarah Cannon Research Institute; and Christine M. Lovly, Vanderbilt-Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.2294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903999PMC
April 2018

An Observational Study of the Association of Video- Versus Text-Based Informed Consent With Multicenter Trial Enrollment: Lessons From the PALM Study (Patient and Provider Assessment of Lipid Management).

Circ Cardiovasc Qual Outcomes 2018 04;11(4):e004675

Department of Medicine (A.C.F., A.M.N., E.D.P., T.Y.W.) and Duke Clinical Research Institute (A.C.F., A.M.N., E.D.P., T.Y.W., S.L., L.E.W., V.M.,), Duke University Medical Center, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCOUTCOMES.118.004675DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891825PMC
April 2018

Nutritional Ketosis and Mitohormesis: Potential Implications for Mitochondrial Function and Human Health.

J Nutr Metab 2018 11;2018:5157645. Epub 2018 Feb 11.

Department of Human Sciences, College of Education and Human Ecology, The Ohio State University, Columbus, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/5157645DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828461PMC
February 2018

Genomic Profiling of Small-Bowel Adenocarcinoma.

JAMA Oncol 2017 Nov;3(11):1546-1553

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.1051DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710195PMC
November 2017

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.

Mol Cancer Ther 2017 11 23;16(11):2598-2608. Epub 2017 Aug 23.

Division of Hematology/Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, California.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/lookup/doi/10.1158/1535-7163.MCT
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-17-0386DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670009PMC
November 2017

Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.

J Immunother Cancer 2017 09 19;5(1):75. Epub 2017 Sep 19.

Department of Surgery, University of California, San Francisco, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0281-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604145PMC
September 2017

Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.

J Thorac Oncol 2017 07;12(7):e89-e90

Memorial Cancer Institute, Memorial Healthcare System, Hollywood, Florida.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.02.017DOI Listing
July 2017

Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies.

JCO Precis Oncol 2017 06 27;1. Epub 2017 Apr 27.

Department of Medicine, Division of Hematology/Oncology, and Center for Personalized Cancer Therapy, University of California San Diego, Moores Cancer Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.16.00004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495179PMC
June 2017

Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response.

Eur Urol Focus 2016 Jun 9;2(2):204-209. Epub 2015 Dec 9.

Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2015.11.007DOI Listing
June 2016